Hiroyuki Minemura
Overview
Explore the profile of Hiroyuki Minemura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki Y, Lee T, Togawa R, Sato R, Yamada R, Tomita H, et al.
IDCases
. 2024 Sep;
38:e02081.
PMID: 39309037
complex (BCC) has been recognized as a serious cause of pneumonia in patients with cystic fibrosis. BCC infection has also been reported in non-cystic fibrosis patients. Notably, the mortality rate...
2.
Shibata Y, Minemura H, Suzuki Y, Nikaido T, Tanino Y, Rikimaru M, et al.
Respir Investig
. 2024 May;
62(4):681-684.
PMID: 38781788
DOATS score and DOAT score, COVID-19 progression prediction tools we have developed, utilize clinical information such as presence of diabetes/obesity (DO), age (A), body temperature (T), and oxygen saturation (S)....
3.
Nikaido T, Tanino Y, Sato Y, Togawa R, Watanabe N, Wang X, et al.
Pathol Int
. 2024 Apr;
74(6):352-355.
PMID: 38651922
No abstract available.
4.
Nikaido T, Tanino Y, Sato Y, Togawa R, Kawamata T, Watanabe N, et al.
Respirol Case Rep
. 2024 Feb;
12(2):e01301.
PMID: 38384743
Forced vital capacity has been utilized as a parameter of disease progression in idiopathic pulmonary fibrosis (IPF); however, its measurement is difficult when patients do not understand or cooperate. Dynamic...
5.
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, et al.
Cancer Sci
. 2024 Jan;
115(4):1273-1282.
PMID: 38287788
Durvalumab has been administered to patients with unresectable stage III non-small cell lung cancer (NSCLC). However, it remains unclear whether durvalumab benefits these patients with epidermal growth factor receptor (EGFR)...
6.
Brandstetter D, Helbig C, Osawa K, Minemura H, Anzai Y, Torisu T, et al.
J Pharm Sci
. 2023 Nov;
113(4):891-899.
PMID: 37926233
During biopharmaceutical development, particle monitoring and characterization are crucial. Notably, particles can be impurities considered as critical quality attribute, or active pharmaceutical ingredient (e.g., viral vectors) or drug delivery system...
7.
Shibata Y, Omae K, Minemura H, Suzuki Y, Nikaido T, Tanino Y, et al.
BMC Pulm Med
. 2023 Aug;
23(1):312.
PMID: 37641057
Background: During the fifth wave of the coronavirus disease 2019 (COVID-19) pandemic in Japan, which took place between June and September 2021, a significant number of COVID-19 cases with deterioration...
8.
Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, et al.
Oncology
. 2023 Aug;
102(1):30-42.
PMID: 37598676
Introduction: Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination)...
9.
Imai H, Wasamoto S, Tsuda T, Nagai Y, Kishikawa T, Masubuchi K, et al.
Thorac Cancer
. 2023 Jul;
14(25):2567-2578.
PMID: 37469246
Background: Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb-Plt-PEM) in nonsquamous non-small cell lung cancer (non-sq NSCLC) are unclear. We investigated the Glasgow Prognostic (GP)...
10.
Suzuki Y, Saito J, Fukuhara A, Rikimaru M, Morimoto J, Lee T, et al.
Am J Med
. 2023 Feb;
136(6):e117-e118.
PMID: 36828210
No abstract available.